What is Toujeo?
Toujeo is a brand name for insulin glargine, which is a long-acting insulin used to control high blood sugar levels in people with diabetes. It is manufactured by Sanofi, a French pharmaceutical company. Toujeo is available in the form of a prefilled insulin pen called Toujeo SoloStar, which contains 450 units of insulin glargine, and Toujeo Max SoloStar, which contains 900 units of insulin glargine.
Toujeo works by replacing the insulin that the body produces naturally but is unable to produce in high enough quantities in people with diabetes. It helps glucose enter the cells of the body, where it can be used for energy.
Toujeo was approved by the U.S. Food and Drug Administration (FDA) in 2015. It is recommended for use in adults with type 1 or type 2 diabetes who require long-acting insulin to control their blood sugar levels. In 2019, the FDA expanded the use of Toujeo to include children with diabetes.
As with all medications, Toujeo may cause side effects, including low blood sugar levels (hypoglycemia) and injection site reactions such as redness, swelling, and itching. It is important to follow the instructions provided by the healthcare provider and to monitor blood sugar levels regularly while taking Toujeo.
Sanofi offers a copay program to help patients with the cost of Toujeo. This program is not valid for prescriptions covered by or submitted for reimbursement under Medicare , Medicaid, VA, DOD, TRICARE, or any other federal or state-funded healthcare program.
Overall, Toujeo is a long-acting insulin that provides a treatment option for people with diabetes to control their blood sugar levels. It is important to discuss the use of Toujeo with a healthcare provider to determine if it is the right treatment option for an individual.
Frequently Asked Questions about toujeo
Prescription Toujeo is a long-acting man-made insulin used to control high blood sugar in adults and children who are 6 years of age and older with diabetes mellitus.
Toujeo contains insulin glargine, which is a long-acting insulin. This drug is given as a subcutaneous injection (an injection under your skin). It's available in the following two prefilled pens: Toujeo SoloStar.
Toujeo 300 U/mL Solostar is a long-acting type of insulin used to treat types 1 and 2 diabetes mellitus in both adults and children. It provides a steady level of insulin in the body for an entire day and helps control blood sugar levels. This helps to prevent complications of diabetes.
French drugmaker Sanofi (Euronext: SAN) has announced the beginning of supplies of its next-generation basal insulin Toujeo Solostar, which is produced at its Russian Sanofi Vostok plant in the Oryol region to the countries of the European Union, according to the company.
Both Toujeo and Lantus are long-acting insulins that contain glargine, however Toujeo is more concentrated containing 300 units per mL of glargine, compared to Lantus's 100 units per mL. Researchers discovered that concentrating insulin makes it last longer in the body with less variability in blood levels over time.
Toujeo contains a higher concentration of insulin than Lantus. Each Lantus SoloStar pen contains 100 units of insulin in 1 mL of liquid - with a total of 300 units of insulin in each pen. Toujeo pens contain 300 units of insulin in 1 mL of liquid, making them three times as concentrated as a Lantus pen.
Toujeo has an average rating of 3.9 out of 10 from a total of 45 reviews on Drugs.com. 20% of reviewers reported a positive experience, while 61% reported a negative experience.
"By reducing the number of injections for people who need more long-acting insulin and lowering copay costs – both of which are important to patients – Toujeo Max SoloStar underscores Sanofi's continued commitment to help those living with diabetes."
Toujeo contains a higher concentration of insulin than Lantus. Each Lantus SoloStar pen contains 100 units of insulin in 1 mL of liquid - with a total of 300 units of insulin in each pen. Toujeo pens contain 300 units of insulin in 1 mL of liquid, making them three times as concentrated as a Lantus pen.
Both Toujeo and Lantus are long-acting insulins that contain glargine, however Toujeo is more concentrated containing 300 units per mL of glargine, compared to Lantus's 100 units per mL. Researchers discovered that concentrating insulin makes it last longer in the body with less variability in blood levels over time.
Both Toujeo and Lantus are long-acting insulins that contain glargine, however Toujeo is more concentrated containing 300 units per mL of glargine, compared to Lantus's 100 units per mL. Researchers discovered that concentrating insulin makes it last longer in the body with less variability in blood levels over time.
If you have liver or kidney problems, you may have an increased risk of low blood sugar with Toujeo. Examples of these problems include liver failure and kidney failure.
